A review of preclinical and early human evidence suggests THCV, a non-psychoactive cannabinoid, could help manage metabolic disorders by suppressing appetite and improving insulin sensitivity.
People interested in cannabinoid science, metabolic health researchers, diabetes-focused clinicians
THCV suppresses appetite and improves insulin sensitivity in preclinical studies
What the researchers found
THCV acts as a CB1 receptor antagonist and partial CB2 agonist, which in preclinical studies translated to appetite suppression, improved insulin sensitivity, enhanced glucose uptake, and reduced fat accumulation. Preliminary human trials showed possible appetite and blood sugar modulation.
Why it matters
With obesity and diabetes rates climbing globally, a non-psychoactive cannabinoid that suppresses appetite and improves metabolic function could represent a novel therapeutic avenue.
The numbers in context
Preclinical studies showed improved insulin signaling, reduced lipid accumulation, and appetite suppression. Preliminary human data suggest glycemic control effects.
How the study worked
Narrative review synthesizing preclinical (cell, animal) and preliminary human trial evidence on THCV's effects on metabolic health including obesity and type 2 diabetes.
What this study cannot tell us
Most evidence is preclinical. Human trial data is preliminary with small samples. Optimal dosing, long-term safety, and drug interactions remain unknown. THCV availability in current cannabis products is limited.
How to read the evidence
Primarily preclinical evidence with only preliminary human trial data. Larger clinical trials needed.
When this study was published
2025 review capturing the latest THCV research.
The bigger picture
Most cannabis research focuses on THC and CBD. THCV represents the next wave of cannabinoid science, with a pharmacological profile almost opposite to THC when it comes to appetite and metabolism.
Questions still open
- Will larger human trials confirm THCV's metabolic benefits? Can THCV be produced at scale for therapeutic use? How does THCV interact with diabetes medications?
Common questions
What is THCV?
Can THCV help with weight loss?
Read the original research
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
AIMS neuroscience, 12(1), 32-43
Citation
Mendoza, Scott. (2025). The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.. AIMS neuroscience, 12(1), 32-43. https://doi.org/10.3934/Neuroscience.2025003
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk